Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria

Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria in High Prevalence Young HCC Patients Country.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04069416

Enrollment

241

Registered

2019-08-28

Start date

2004-01-31

Completion date

2019-01-31

Last updated

2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hcc

Keywords

liver transplant, HCC, Extended milan, Living donor liver transplantation

Brief summary

The present study aims to evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients.

Detailed description

Introduction: HEPATOCELLULAR CARCINOMA (HCC) is the second leading cause of cancer mortality worldwide. Living donor liver transplantation (LDLT) for HCC patients has emerged as a rewarding therapy for a cure and a successful alternative where a Deceased donor liver transplantation (DDLT) program is lacking. Therefore, trials for careful expansion to Milan criteria have been adopted. Aim of the study: To evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients

Interventions

PROCEDUREliving donor liver transplantation

liver graft from a living donor

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* All patient transplanted for HCC eligible for transplant (no vascular invasion-no extra hepatic metastasis) * age\>18y

Exclusion criteria

* other etiology for liver transplant rather than HCC * patient not fit for surgery * age \>70y

Design outcomes

Primary

Measure	Time frame	Description
HCC recurrence	3 years	Recurrence of Hepatocellular carcinoma either intra-hepatic, extra-hepatic or both

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026